Month: September 2021

Sep 03 2021

Uncategorized

FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia

by Clinical Editor

No Comments

The FDA has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera) for adults with schizophrenia.

Sep 02 2021

Uncategorized

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval – Psychiatric Times

by Clinical Editor

No Comments

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval  Psychiatric Times Janssen Wins FDA Approval for Long-Acting Schizophrenia Drug  BioSpace FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia  Medscape Janssen Announces US FDA...

Sep 02 2021

Uncategorized

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval

by Clinical Editor

No Comments

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval. The US Food and Drug Administration (FDA) has approved Janssen Pharmaceutical’s long-acting …

Sep 02 2021

Uncategorized

FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia

by Clinical Editor

No Comments

The FDA has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera) for adults with schizophrenia.

Sep 02 2021

Uncategorized

FDA clears J&J’s twice-yearly Invega for schizophrenia

by Clinical Editor

No Comments

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit …

Sep 02 2021

Uncategorized

Patients with schizophrenia at different stages show varied deficits in discriminating rewarding values

by Clinical Editor

No Comments

Anhedonia and amotivation are key features of negative symptoms observed in patients with schizophrenia. In particular, amotivation refers to the diminished volition to initiate or maintain …

Sep 02 2021

Uncategorized

Janssen Wins FDA Approval for Long-Acting Schizophrenia Drug

by Clinical Editor

No Comments

Janssen-Wins-FDA-Approval-for-Long-Acting-Schizophrenia-Drug-BioSpace-9-1-21.jpeg The U.S. Food and Drug Administration (FDA) greenlit Janssen ’s long-acting, twice-per-year schizophrenia drug Invega …

Sep 01 2021

Uncategorized

Miami police search for missing man with bipolar disorder, schizophrenia – WPLG Local 10

by Clinical Editor

No Comments

Miami police search for missing man with bipolar disorder, schizophrenia  WPLG Local 10

Sep 01 2021

Uncategorized

FDA accepts Teva-MedinCell’s new drug application for schizophrenia drug

by Clinical Editor

No Comments

The US Food and Drug Administration (FDA) has accepted Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM, to treat schizophrenia. TV-46000 is an extended …

Sep 01 2021

Uncategorized

Miami police search for missing man with bipolar disorder, schizophrenia

by Clinical Editor

No Comments

Police say Brockington has been diagnosed with bipolar disorder and schizophrenia. Anyone with information about his whereabouts is asked to call the City of Miami Police Department Special Victims …